Equities research analysts forecast that PolyPid Ltd. (NASDAQ:PYPD) will announce earnings per share of ($0.66) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for PolyPid’s earnings. PolyPid posted earnings of ($0.35) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 88.6%. The business is scheduled to announce its next earnings report on Wednesday, November 10th.
On average, analysts expect that PolyPid will report full year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($2.19). For the next year, analysts expect that the business will post earnings of ($2.21) per share, with EPS estimates ranging from ($2.34) to ($2.08). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow PolyPid.
PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.02).
PYPD stock traded down $0.28 during midday trading on Thursday, reaching $7.50. 100 shares of the company’s stock traded hands, compared to its average volume of 47,186. The company has a 50-day moving average price of $8.12 and a two-hundred day moving average price of $8.65. PolyPid has a 52 week low of $6.95 and a 52 week high of $16.50. The firm has a market capitalization of $127.85 million, a PE ratio of -4.19 and a beta of 0.30.
Several hedge funds have recently made changes to their positions in the company. Morgan Stanley bought a new stake in PolyPid in the 2nd quarter valued at $32,000. Geode Capital Management LLC purchased a new stake in PolyPid in the 2nd quarter valued at about $101,000. Cresset Asset Management LLC purchased a new stake in PolyPid in the 2nd quarter valued at about $106,000. Meitav Dash Investments Ltd. bought a new stake in shares of PolyPid in the 2nd quarter valued at about $131,000. Finally, Renaissance Technologies LLC bought a new stake in shares of PolyPid in the 2nd quarter valued at about $174,000. Hedge funds and other institutional investors own 9.64% of the company’s stock.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.
Featured Article: Why are percentage gainers important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.